655 reports of this reaction
5.7% of all BARICITINIB reports
#2 most reported adverse reaction
OFF LABEL USE is the #2 most commonly reported adverse reaction for BARICITINIB, manufactured by Eli Lilly and Company. There are 655 FDA adverse event reports linking BARICITINIB to OFF LABEL USE. This represents approximately 5.7% of all 11,538 adverse event reports for this drug.
Patients taking BARICITINIB who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among BARICITINIB users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for BARICITINIB:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 655 FDA reports for BARICITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 5.7% of all adverse event reports for BARICITINIB, making it one of the most commonly reported side effect.
If you experience off label use while taking BARICITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.